NUI Maynooth spinout Avectas has added $20m to its coffers to develop cancer treatments.

GV and Takeda have backed a series B round that will fund the Rockefeller University spinout's identification of targets for brain disease treatments.

GV and returning investor Takeda Ventures chipped into a series B round that will fund the identification of targets for brain disease treatments.

MemorialCare Innovation Fund led a series B round featuring UnityPoint Health Ventures and OSF Ventures, taking SilverCloud's total funding past $30m.

What do you do after you have launched a spinout that has raised venture capital from illustrious backers such as pharmaceutical firm Novo, care provider Kaiser Permanente and medical device manufacturer St Jude Medical, and successfully gone public through a $107m initial public offering?

A host of corporate and government-backed initiatives have been launched to tackle the coronavirus that develops into the Covid-19 disease. In a global, fast-moving pandemic, this can only be a snapshot of the efforts at the end of March 2020.

Mental health treatment app provider SilverCloud Health has now raised more than $30m, having spun out of Trinity College Dublin in 2012.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Tsinghua-run incubator Lotus Lake Capital has backed Insight Lifetech, which develops treatment and diagnostic tools for coronary heart disease.

The SiBionics-backed heart disease device developer secured $28.4m in a round led by SDIC Gaoxin Industrial Investment.